Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
4.5 EUR
−5.16 M EUR
97.00 M EUR
7.09 M
About COSMO PHARM N
Sector
CEO
Giovanni di Napoli
Headquarters
Dublin
Website
Founded
2016
ISIN
NL0011832936
FIGI
BBG00CWZRBW1
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of C43 is 67.0 EUR — it has decreased by −0.74% in the past 24 hours. Watch COSMO PHARMACEUT. EO-,26 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange COSMO PHARMACEUT. EO-,26 stocks are traded under the ticker C43.
C43 stock has fallen by −2.88% compared to the previous week, the month change is a −14.01% fall, over the last year COSMO PHARMACEUT. EO-,26 has showed a 79.14% increase.
We've gathered analysts' opinions on COSMO PHARMACEUT. EO-,26 future price: according to them, C43 price has a max estimate of 141.42 EUR and a min estimate of 84.31 EUR. Watch C43 chart and read a more detailed COSMO PHARMACEUT. EO-,26 stock forecast: see what analysts think of COSMO PHARMACEUT. EO-,26 and suggest that you do with its stocks.
C43 stock is 1.49% volatile and has beta coefficient of 0.76. Track COSMO PHARMACEUT. EO-,26 stock price on the chart and check out the list of the most volatile stocks — is COSMO PHARMACEUT. EO-,26 there?
Today COSMO PHARMACEUT. EO-,26 has the market capitalization of 1.10 B, it has decreased by −3.32% over the last week.
Yes, you can track COSMO PHARMACEUT. EO-,26 financials in yearly and quarterly reports right on TradingView.
COSMO PHARMACEUT. EO-,26 is going to release the next earnings report on Mar 19, 2025. Keep track of upcoming events with our Earnings Calendar.
C43 net income for the last half-year is 75.88 M EUR, while the previous report showed −6.61 M EUR of net income which accounts for 1.25 K% change. Track more COSMO PHARMACEUT. EO-,26 financial stats to get the full picture.
Yes, C43 dividends are paid annually. The last dividend per share was 2.00 EUR. As of today, Dividend Yield (TTM)% is 3.02%. Tracking COSMO PHARMACEUT. EO-,26 dividends might help you take more informed decisions.
As of Nov 13, 2024, the company has 325.00 employees. See our rating of the largest employees — is COSMO PHARMACEUT. EO-,26 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. COSMO PHARMACEUT. EO-,26 EBITDA is 98.41 M EUR, and current EBITDA margin is 20.43%. See more stats in COSMO PHARMACEUT. EO-,26 financial statements.
Like other stocks, C43 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade COSMO PHARMACEUT. EO-,26 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So COSMO PHARMACEUT. EO-,26 technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating COSMO PHARMACEUT. EO-,26 stock shows the neutral signal. See more of COSMO PHARMACEUT. EO-,26 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.